NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, and SynergyFinder™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally.

Recently NTRC, based at Pivot Park, shared three press-releases:

Kinetic parameters of 80 kinase inhibitors available online through the Journal of Molecular Biology

NTRC has made available the kinetic data of 80 kinase inhibitors on their targets in a research article in the Journal of Molecular Biology. This is the largest data base of association and dissociation rate constants of kinase inhibitors available to date. In total, 46 protein tyrosine, serine/threonine and lipid kinases were studied, including well-known drug targets such as the epidermal growth factor receptor (EGFR) and the δ-isoform of phosphoinositide 3-kinase (PI3Kδ). Kinetic constants were determined on NTRC’s ResidenceTimer™ platform using recombinant kinases from Carna Biosciences, Inc. (Kobe, Japan).

Read further (published January 2nd 2017)

Structural insight into the function of TDO in healthy aging

Researchers from the European Research Institute for the Biology of Aging (ERIBA) University of Groningen, the Netherlands) in collaboration with the Netherlands Translational Research Center B.V. have identified an evolutionary conserved structural loop in the enzyme TDO that is critical for its function. When absent, it increases the motility and the lifespan of the roundworm Caenorhabditis elegans. The structural element was identified in a genetic screen by the group of Dr. Ellen Nollen at ERIBA.

Read further (published December 23rd 2016)

New drug combinations addressing treatment resistance in childhood leukemia proposed based on SynergyFinder™

Researchers from the Princess Máxima Center for Pediatric Oncology in Utrecht (The Netherlands) in collaboration with researchers from Erasmus Medical Center in Rotterdam have identified mechanisms underlying resistance to steroid therapy in childhood T-cell acute lymphoblastic leukemia (T-ALL). In the article, which appeared today in the open access online journal PLOS Medicine, new approaches to therapy of childhood T-ALL are proposed based on SynergyFinder™ studies performed at NTRC.

Read further (published December 20th 2016)

Back